Login to Your Account

Clinic Roundup

Wednesday, August 17, 2011
Optimer Pharmaceuticals Inc., of San Diego, said a subgroup analysis of patients with Clostridium difficile-associated diarrhea (CDAD) receiving concomitant systemic antibiotics in two Phase III trials found that, in those patients, Dificid (fidaxomicin) achieved a significantly higher initial clinical cure rate and higher rate of global cure when compared to vancomycin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription